Literature DB >> 11800467

Susceptibility testing of Mycobacterium tuberculosis to pyrazinamide.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11800467     DOI： 10.1099/0022-1317-51-1-11

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN： 0022-2615            Impact factor:   2.472


× No keyword cloud information.
  17 in total

1.  Evaluation of colorimetric methods using nicotinamide for rapid detection of pyrazinamide resistance in Mycobacterium tuberculosis.

Authors:  Niuris C Mirabal; Sergio L Yzquierdo; Dihadenys Lemus; Mariela Madruga; Yoslaine Milián; Miguel Echemendía; Howard Takiff; Anandi Martin; Patrick Van der Stuyf; Juan Carlos Palomino; Ernesto Montoro
Journal:  J Clin Microbiol       Date:  2010-06-16       Impact factor: 5.948

2.  Mycobacterium tuberculosis pncA Polymorphisms That Do Not Confer Pyrazinamide Resistance at a Breakpoint Concentration of 100 Micrograms per Milliliter in MGIT.

Authors:  Michael G Whitfield; Robin M Warren; Elizabeth M Streicher; Samantha L Sampson; Frik A Sirgel; Paul D van Helden; Alexandra Mercante; Melisa Willby; Kelsey Hughes; Kris Birkness; Glenn Morlock; Annelies van Rie; James E Posey
Journal:  J Clin Microbiol       Date:  2015-08-19       Impact factor: 5.948

3.  Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing.

Authors:  J Werngren; E Sturegård; P Juréen; K Ängeby; S Hoffner; T Schön
Journal:  Antimicrob Agents Chemother       Date:  2011-12-27       Impact factor: 5.191

4.  Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance.

Authors:  A H Diacon; P R Donald; A Pym; M Grobusch; R F Patientia; R Mahanyele; N Bantubani; R Narasimooloo; T De Marez; R van Heeswijk; N Lounis; P Meyvisch; K Andries; D F McNeeley
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

Review 5.  Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses.

Authors:  Kwok Chiu Chang; Wing Wai Yew; Ying Zhang
Journal:  Antimicrob Agents Chemother       Date:  2011-07-18       Impact factor: 5.191

6.  Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis.

Authors:  Mary A De Groote; Janet C Gilliland; Colby L Wells; Elizabeth J Brooks; Lisa K Woolhiser; Veronica Gruppo; Charles A Peloquin; Ian M Orme; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

7.  Widespread pyrazinamide-resistant Mycobacterium tuberculosis family in a low-incidence setting.

Authors:  Dao Nguyen; Paul Brassard; Jennifer Westley; Louise Thibert; Melanie Proulx; Kevin Henry; Kevin Schwartzman; Dick Menzies; Marcel A Behr
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

8.  Uncoupling Environmental pH and Intrabacterial Acidification from Pyrazinamide Susceptibility in Mycobacterium tuberculosis.

Authors:  Nicholas D Peterson; Brandon C Rosen; Nicholas A Dillon; Anthony D Baughn
Journal:  Antimicrob Agents Chemother       Date:  2015-09-14       Impact factor: 5.191

9.  Prevention of false resistance results obtained in testing the susceptibility of Mycobacterium tuberculosis to pyrazinamide with the Bactec MGIT 960 system using a reduced inoculum.

Authors:  Claudio Piersimoni; Alessandro Mustazzolu; Federico Giannoni; Stefano Bornigia; Giancarlo Gherardi; Lanfranco Fattorini
Journal:  J Clin Microbiol       Date:  2012-10-24       Impact factor: 5.948

10.  Genomic characterization of an endemic Mycobacterium tuberculosis strain: evolutionary and epidemiologic implications.

Authors:  Dao Nguyen; Paul Brassard; Dick Menzies; Louise Thibert; Rob Warren; Serge Mostowy; Marcel Behr
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.